The Phase 2 study enrolled 51 patients aged 50+ randomized 1:1:1 to receive a single subretinal injection of OCU410 at 1×10^10 or 3×10^10 vector genomes per eye or control. Ocugen plans to initiate a Phase 3 registrational trial in Q3 2026 with up to 300 subjects and an adaptive design powered over 95%, targeting a BLA filing. In the ArMaDa trial, OCU410 at the medium dose achieved a 31% reduction in geographic atrophy lesion growth versus control at 12 months (p<0.05), alongside a 27% slower rate of ellipsoid zone loss. Fifty-five percent of treated patients experienced at least a 30% lesion size reduction, and a subgroup with baseline lesions 5–17.5 mm² saw a 33% decrease. OCU410 displayed a clean safety profile with no related serious adverse events or adverse events of special interest, including no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy. These results align with the favorable safety findings from the earlier Phase 1 study. Geographic atrophy affects 2–3 million patients in the US and Europe and contributes to vision loss in a global dry AMD population of 266 million. Current treatments require 6–12 annual injections, whereas OCU410’s one-time gene therapy could reduce treatment burden, improve adherence, and address multiple disease pathways.